

Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps

Carsuzaa, Florent; Lapeyre, Michel; Gregoire, Vincent; Maingon, Philippe; Beddok, Arnaud; Marcy, Pierre-yves; Salleron, Julia; Coutte, Alexandre; Racadot, Severine; Pointreau, Yoann; Graff, Pierre; Beadle, Beth; Benezery, Karen; Biau, Julian; Calugaru, Valentin; Castelli, Joel; Chua, Melvin; Di Rito, Alessia; Dore, Melanie; Ghadjar, Pirus

DOI:

[10.1016/j.radonc.2021.04.026](https://doi.org/10.1016/j.radonc.2021.04.026)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Carsuzaa, F, Lapeyre, M, Gregoire, V, Maingon, P, Beddok, A, Marcy, P, Salleron, J, Coutte, A, Racadot, S, Pointreau, Y, Graff, P, Beadle, B, Benezery, K, Biau, J, Calugaru, V, Castelli, J, Chua, M, Di Rito, A, Dore, M, Ghadjar, P, Huguot, F, Jardel, P, Johansen, J, Kimple, R, Krengli, M, Laskar, S, Mcdowell, L, Nichols, A, Tribius, S, Valduvico, I, Hu, C, Liem, X, Moya-plana, A, D'onofrio, I, Parvathanen, U, Takiar, V, Orlandi, E, Psyrrri, A, Shenouda, G, Sher, D, Steuer, C, Shan Sun, X, Tao, Y, Thomson, D, Tsai, M, Vulquin, N, Gorphe, P, Mehanna, H, Yom, SS, Bourhis, J & Thariat, J 2021, 'Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: a GORTEC internationally-reviewed HNCIG-endorsed consensus', *Radiotherapy & Oncology*, vol. 160, pp. 140-147. <https://doi.org/10.1016/j.radonc.2021.04.026>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 19. Apr. 2024

Radiotherapy and Oncology

Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: a GORTEC internationally reviewed consensus --Manuscript Draft--

Manuscript Number:	RADONC-D-21-00509
Article Type:	Full length article
Section/Category:	Head & Neck Cancers
Keywords:	head and neck; cancer; Radiotherapy; postoperative; reconstructive surgery; flap; consensus; recommendation
Corresponding Author:	juliette thariat, MD PhD centre Baclesse Caen, FRANCE
First Author:	Florent Carsuzaa, MD
Order of Authors:	Florent Carsuzaa, MD Michel Lapeyre, MD Vincent Gregoire, MD Philippe Maingon, MD Arnaud Beddok, MD Pierre-Yves Marcy, MD Julia Salleron, MSc Alexandre Coutte, MD Severine Racadot, MD Yoann Pointreau, MD Pierre Graff, MD Beth Beadle, MD Karen Benezery, MD Julian Biau, MD Valentin Calugaru, MD Joel Castelli, MD Melvin Chua, MD Alessia Di Rito, MD Melanie Dore, MD Pirus Ghadjar, MD Florence Huguet, MD PhD Pauline Jardel, MD Jorgen Johansen, MD Randall Kimple, MD Marco Krengli, MD Sarbani Laskar, MD Lachlan Mcdowell, MD Anthony Nichols, MD

Silke Tribius, MD
Izaskun Valduvieto, MD
Chaosu Hu, MD
Xavier Liem, MD
Antoine Moya-Plana, MD
Ida D'onofrio, MD
Upendra Parvathanen, MD
Vinita Takiar, MD
Ester Orlandi, MD
Amanda Psyrrri, MD
George Shenouda, MD
David Sher, MD
Conor Steuer, MD
Xu Shan Sun, MD
Yungan Tao, MD
David Thomson, MD
Mu-Hung Tsai, MD
Noemie Vulquin, MD
Philippe Gorphe, MD
Hisham Mehanna, MD PhD
Sue S. Yom, MD
Jean Bourhis, MD PhD
juliette thariat, MD PhD

Abstract:

Introduction

Head and neck reconstructive surgery using a flap is increasingly common. Best practices and outcomes for postoperative radiotherapy (poRT) with flaps have not been specified. We aimed to provide consensus recommendations to assist clinical decision-making highlighting areas of uncertainty in the presence of flaps.

Material and methods

Radiation, medical, and surgical oncologists were assembled from GORTEC and internationally. The consensus-building approach covered 59 topics across four domains: 1) identification of postoperative tissue changes on imaging for flap delineation, 2) understanding of tumor relapse risks and target volume definitions, 3) functional radiation-induced deterioration, 4) feasibility of flap avoidance.

Results

Across the 4 domains, international consensus (median score $\geq 7/9$) was achieved only for functional deterioration (73.3%); other consensus rates were 55.6% for poRT avoidance of flap structures, 41.2% for flap definition and 11.1% for tumor spread patterns. Radiation-induced flap fibrosis or atrophy and their functional impact was well recognized while flap necrosis was not, suggesting dose-volume adaptation for the former. Flap avoidance was recommended to minimize bone flap osteoradionecrosis but not soft-tissue toxicity. The need for identification (CT planning, fiducials, accurate operative report) and targeting of the junction area at risk between native tissues and flap was well recognized. Experts variably considered flaps as prone to tumor dissemination or not. Discrepancies in rating of 11 items among international reviewing

participants are shown.

Conclusion

International recommendations were generated for the management of flaps in head and neck radiotherapy. Considerable knowledge gaps hinder further consensus, in particular with respect to tumor spread patterns.

COVER LETTER

This manuscript entitled : **Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: a GORTEC internationally reviewed consensus**

This timely article provides a consensus recommendations reviewed by international experts to assist clinical decision-making highlighting areas of uncertainty in the presence of flaps.

Best regards.

Prof. Juliette Thariat

Centre François-Baclesse, département de radiothérapie, 3, avenue Général-Harris, 14000 Caen, France ; Laboratoire de physique corpusculaire IN2P3/ENSICAEN - UMR6534, boulevard du Marechal-Juin, 14050 Caen, France.

Electronic address: jthariat@gmail.com

A handwritten signature in black ink, consisting of a stylized 'J' followed by a large, sweeping loop that extends to the right and then curves back down.

HIGHLIGHTS

1. Our GORTEC internationally-reviewed consensus showed that the flap-tissue junction should be considered at higher risk of tumor spread compared to other areas of the flap and that postoperative planning should be based on a contrast-enhanced CT;
2. Surgeons should report the placement of flaps more accurately and consider clip placement to guide radiotherapy planning;
3. The risks of radiation-induced atrophy, fibrosis, and osteoradionecrosis should be considered and the maximum and mean doses limited by radiotherapy optimization

Title page : **Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: an international consensus from the GORTEC**

Running title : **Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps**

Florent Carsuzaa¹, Michel Lapeyre², Vincent Gregoire³, Philippe Maingon⁴, Arnaud Beddok⁵, Pierre-Yves Marcy⁶, Julia Salleron⁷, Alexandre Coutte⁸, Severine Racadot³, Yoann Pointreau⁹, Pierre Graff¹⁰, Beth Beadle¹¹, Karen Benezery¹², Julian Biau², Valentin Calugaru⁵, Joel Castelli¹³, Melvin Chua¹⁴, Alessia Di Rito¹⁵, Melanie Dore¹⁶, Pirus Ghadjjar¹⁷, Florence Huguet¹⁸, Pauline Jardel¹⁹, Jorgen Johansen²⁰, Randall Kimple²¹, Marco Krengli²², Sarbani Laskar²³, Lachlan Mcdowell²⁴, Anthony Nichols²⁵, Silke tribius²⁶, Izaskun Valduvico²⁷, Chaosu Hu²⁸, Xavier Liem²⁹, Antoine Moya-Plana³⁰, Ida D'onofrio³¹, Upendra Parvathanen³², Vinita Takiar³³, Ester Orlandi³⁴, Amanda Psyrris³⁵, George Shenouda³⁶, David Sher³⁷, Conor Steuer³⁸, Xu Shan Sun³⁹, Yungan Tao³⁰, David Thomson⁴⁰, Mu-Hung Tsai⁴¹, Noemie Vulquin⁴², Philippe Gorphe³⁰, Hisham Mehanna⁴³, Sue S. Yom⁴⁴, Jean Bourhis⁴⁵, Juliette Thariat⁴⁶

1 Department of Head and Neck Surgery, CHU de Poitiers, France.

2 Department of Radiation oncology, Centre Jean Perrin – Clermont-Ferrand, France.

3 Department of Radiation oncology, Centre Léon Bérard, Lyon, France.

4 Department of Radiation Oncology, Hôpital de la Pitié-Salpêtrière, Paris, France.

5 Department of Radiation Oncology, Institut Curie, Paris, France

6 Department of Radiology, Clinique du Cap d'Or, La Seyne-sur-mer, France.

7 Department of Biostatistics, Institut de cancérologie de Lorraine, France

8 Department of Radiation Oncology, Amiens Picardie University Medical Center, Amiens, France

9 Department of Radiation Oncology, Centre Jean Bernard, Le Mans, France.

10 Department or Radiation Oncology, Institut C. Regaud, Toulouse, France.

11 Department of Radiation Oncology, Stanford University Medical Center, CA, USA. Stanford University Medical Center

12 Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France.

13 Department of Radiation Oncology, Centre Eugène Marquis, Rennes, France.

14 Department of Medical oncology, National Cancer Centre Singapore, Malaysia.

15 Department of Radiation Oncology, OC Radioterapia Ospedale "Mons. A.R. Dimiccoli" di Barletta, Rome, Italy

16 Department of Radiation Oncology, Institut de cancérologie de l'Ouest, St Herblain, France.

17 Department of Radiation Oncology, Charité, Berlin, Germany.

18 Department of Radiation Oncology, Hospital de Tenon, Paris, France.

19 Department of Radiation Oncology, CHU de la Milétrie, Poitiers, France.

20 Department of Radiation Oncology, Odense University Hospital, Denmark.

21 Department of Medical Oncology, University of Wisconsin-Madison, WI, USA.

22 Department of Translational Medicine University of Piemonte Orientale, Novara, Italy

23 Department of Radiation Oncology, TATA, Mumbai, India.

- 24 Department of Radiation Oncology, Peter McCallum Cancer Center, Melbourne, Australia.
- 25 Department of Head and Neck surgery, London Health Sciences Center, Ontario, Canada.
- 26 Department of Radiation Oncology, Hermann-Holthusen-Institute for Radiation Oncology, Asklepios Hospital St. Georg, Hamburg, Germany.
- 27 Department of Radiation Oncology, Hospital clinic, Barcelona, Spain.
- 28 Department of Radiation Oncology, Fundan University, Shanghai, China.
- 29 Department of Radiation Oncology, Centre Oscar Lambret, Lille.
- 30 Department of Head and Neck Surgery, Gustave Roussy, Villejuif, France.
- 31 Department of Radiation Oncology, Hospital Naples, Italy.
- 32 Department of Radiation Oncology, University of Washington, DC, USA.
- 33 Department of Radiation Oncology, University of Cincinnati, Ohio, USA.
- 34 Department of Radiation Oncology, CNAO, Milan, Italy.
- 35 Department of Medical Oncology, Attikon University Hospital, Athens, Greece.
- 36 Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec.
- 37 Department of Radiation Oncology, UT Southwestern, Dallas, USA.
- 38 Department of Head and Neck Surgery, Winship Cancer Institute, Atlanta, USA.
- 39 Department of Radiation Oncology, Centre Hospitalier André Bouloche, Montbéliard, France.
- 40 Department of Radiation Oncology, The Christie NHS Foundation Trust, Manchester, UK.
- 41 Department of Radiation Oncology, National Cheng Kung University Hospital, Tainan, Taiwan.
- 42 Department of Radiation Oncology, Centre Georges François Leclerc, Dijon, France.
- 43 Department of Radiation Oncology, Institute for Global Innovation, Birmingham, UK.
- 44 Department of Radiation Oncology, NRG Oncology Cancer Research Group, California, USA.
- 45 Department of Radiation Oncology, UNIL-CHUV, Lausanne, Suisse.
- 46 Department of Radiation Oncology, Centre François-Baclesse, Caen, France.

Disclosures : None

Funding : None

Conflict of Interest : None

Authors' contributions : each author has contributed significantly (FC, ML, VG, AB, PYM, AC, SR, JB, JT designed the questions, JS did the statistics, others quoted the proposals, either once (independent international review group) or twice (GORTEC quotation group), all reviewed the final ms) to the manuscript.

Address for reprints / to corresponding author: Juliette Thariat / email : jthariat@gmail.com

Centre François-Baclesse, département de radiothérapie, 3, avenue Général-Harris, 14000 Caen, France ; Laboratoire de physique corpusculaire IN2P3/ENSICAEN - UMR6534, boulevard du Marechal-Juin, 14050 Caen, France.

Corresponding author : Pr Juliette Thariat / email : jthariat@gmail.com

Responsible statistical analysis author : Julia Salleron / email : j.salleron@nancy.unicancer.fr

Title: Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: an international consensus from the GORTEC

Authors: Affiliations + group belonging: GORTEC / HNCIG

Florent Carsuzaa¹, Michel Lapeyre², Vincent Gregoire³, Philippe Maingon⁴, Arnaud Beddok⁵, Pierre-Yves Marcy⁶, Julia Salleron⁷, Alexandre Coutte⁸, Severine Racadot³, Yoann Pointreau⁹, Pierre Graff¹⁰, Beth Beadle¹¹, Karen Benezery¹², Julian Biau², Valentin Calugaru⁵, Joel Castelli¹³, Melvin Chua¹⁴, Alessia Di Rito¹⁵, Melanie Dore¹⁶, Pirus Ghadjar¹⁷, Florence Huguet¹⁸, Pauline Jardel¹⁹, Jorgen Johansen²⁰, Randall Kimple²¹, Marco Krengli²², Sarbani Laskar²³, Lachlan Mcdowell²⁴, Anthony Nichols²⁵, Silke tribius²⁶, Izaskun Valduvico²⁷, Chaosu Hu²⁸, Xavier Liem²⁹, Antoine Moya-Plana³⁰, Ida D'onofrio³¹, Upendra Parvathanen³², Vinita Takiar³³, Ester Orlandi³⁴, Amanda Psyrris³⁵, George Shenouda³⁶, David Sher³⁷, Conor Steuer³⁸, Xu Shan Sun³⁹, Yungan Tao³⁰, David Thomson⁴⁰, Mu-Hung Tsai⁴¹, Noemie Vulquin⁴², Philippe Gorphe³⁰, Hisham Mehanna⁴³, Sue S. Yom⁴⁴, Jean Bourhis⁴⁵, Juliette Thariat⁴⁶

Affiliations

- 1 Department of Head and Neck Surgery, CHU de Poitier, France.
- 2 Department of Radiation oncology, Centre Jean Perrin - Clermont-Ferrand, France.
- 3 Department of Radiation oncology, Centre Léon Bérard, Lyon, France.
- 4 Department of Radiation Oncology, Hôpital de la Pitié-Salpêtrière, Paris, France.
- 5 Department of Radiation Oncology, Institut Curie, Paris, France
- 6 Department of Radiology, Clinique du Cap d'Or, La Seyne-sur-mer, France.
- 7 Department of Biostatistics, Institut de cancérologie de Lorraine, France
- 8 Department of Radiation Oncology, Amiens Picardie University Medical Center, Amiens, France
- 9 Department of Radiation Oncology, Centre Jean Bernard, Le Mans, France.
- 10 Department or Radiation Oncology, Institut C. Regaud, Toulouse, France.
- 11 Department of Radiation Oncology, Stanford University Medical Center, CA, USA. Stanford University Medical Center
- 12 Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France.
- 13 Department of Radiation Oncology, Centre Eugène Marquis, Rennes, France.
- 14 Department of Medical oncology, National Cancer Centre Singapore, Malaysia.
- 15 Department of Radiation Oncology, OC Radioterapia Ospedale "Mons. A.R. Dimiccoli" di Barletta, Rome, Italy
- 16 Department of Radiation Oncology, Institut de cancérologie de l'Ouest, St Herblain, France.
- 17 Department of Radiation Oncology, Charité, Berlin, Germany.
- 18 Department of Radiation Oncology, Hospital de Tenon, Paris, France.
- 19 Department of Radiation Oncology, CHU de la Milétrie, Poitiers, France.
- 20 Department of Radiation Oncology, Odense University Hospital, Denmark.
- 21 Department of Medical Oncology, University of Wisconsin-Madison, WI, USA.
- 22 Department of Translational Medicine University of Piemonte Orientale, Novara, Italy
- 23 Department of Radiation Oncology, TATA, Mumbai, India.
- 24 Department of Radiation Oncology, Peter McCallum Cancer Center, Melbourne, Australia.
- 25 Department of Head and Neck surgery, London Health Sciences Center, Ontario, Canada.
- 26 Department of Radiation Oncology, Hermann-Holthusen-Institute for Radiation Oncology, Asklepios Hospital St. Georg, Hamburg, Germany.

- 1 27 Department of Radiation Oncology, Hospital clinic, Barcelona, Spain.
2 28 Department of Radiation Oncology, Fundan University, Shanghai, China.
3 29 Department of Radiation Oncology, Centre Oscar Lambret, Lille.
4 30 Department of Head and Neck Surgery, Gustave Roussy, Villejuif, France.
5 31 Department of Radiation Oncology, Hospital Naples, Italy.
6 32 Department of Radiation Oncology, University of Washington, DC, USA.
7 33 Department of Radiation Oncology, University of Cincinnati, Ohio, USA.
8 34 Department of Radiation Oncology, CNAO, Milan, Italy.
9 35 Department of Medical Oncology, Attikon University Hospital, Athens, Greece.
10 36 Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec.
11 37 Department of Radiation Oncology, UT Southwestern, Dallas, USA.
12 38 Department of Head and Neck Surgery, Winship Cancer Institute, Atlanta, USA.
13 39 Department of Radiation Oncology, Centre Hospitalier André Bouloche, Montbéliard,
14 France.
15 40 Department of Radiation Oncology, The Christie NHS Foundation Trust, Manchester, UK.
16 41 Department of Radiation Oncology, National Cheng Kung University Hospital, Tainan,
17 Taiwan.
18 42 Department of Radiation Oncology, Centre Georges François Leclerc, Dijon, France.
19 43 Department of Radiation Oncology, Institute for Global Innovation, Birmingham, UK.
20 44 Department of Radiation Oncology, NRG Oncology Cancer Research Group, California, USA.
21 45 Department of Radiation Oncology, UNIL-CHUV, Lausanne, Suisse.
22 46 Department of Radiation Oncology, Centre François-Baclesse, Caen, France.

23 Financial Support: none

24 Conflict of Interest: no conflicting relationship exists for any author.

25 Running head: Recommendations for postoperative radiotherapy in head & neck squamous
26 cell carcinoma in the presence of flaps.

27 Acknowledgements: Camille Vidaud (Head and Neck Cancer International Group + Gortec) and
28 Nazim Khalladi.

29 Authors ' contributions: each author has contributed significantly to the manuscript.

30 Address for reprints / to corresponding author: Juliette Thariat / Centre François-Baclesse,
31 département de radiothérapie, 3, avenue Général-Harris, 14000 Caen, France ; Laboratoire de
32 physique corpusculaire IN2P3/ENSICAEN - UMR6534, boulevard du Marechal-Juin, 14050
33 Caen, France. Email : jthariat@gmail.com

34 **Corresponding author:**

35 Prof. Juliette Thariat

36 Centre François-Baclesse, département de radiothérapie, 3, avenue Général-Harris, 14000
37 Caen, France ; Laboratoire de physique corpusculaire IN2P3/ENSICAEN - UMR6534, boulevard
38 du Marechal-Juin, 14050 Caen, France. Electronic address: jthariat@gmail.com

1 **Abstract**

2 Introduction: Head and neck reconstructive surgery using a flap is increasingly common. Best
3 practices and outcomes for postoperative radiotherapy (poRT) with flaps have not been
4 specified. We aimed to provide consensus recommendations to assist clinical decision-making
5 highlighting areas of uncertainty in the presence of flaps.

6 Material and methods: Radiation, medical, and surgical oncologists were assembled from
7 GORTEC and internationally. The consensus-building approach covered 59 topics across four
8 domains: 1) identification of postoperative tissue changes on imaging for flap delineation, 2)
9 understanding of tumor relapse risks and target volume definitions, 3) functional radiation-
10 induced deterioration, 4) feasibility of flap avoidance.

11 Results: Across the 4 domains, international consensus (median score $\geq 7/9$) was achieved only
12 for functional deterioration (73.3%); other consensus rates were 55.6% for poRT avoidance of
13 flap structures, 41.2% for flap definition and 11.1% for tumor spread patterns. Radiation-
14 induced flap fibrosis or atrophy and their functional impact was well recognized while flap
15 necrosis was not, suggesting dose-volume adaptation for the former. Flap avoidance was
16 recommended to minimize bone flap osteoradionecrosis but not soft-tissue toxicity. The need
17 for identification (CT planning, fiducials, accurate operative report) and targeting of the
18 junction area at risk between native tissues and flap was well recognized. Experts variably
19 considered flaps as prone to tumor dissemination or not. Discrepancies in rating of 11 items
20 among international reviewing participants are shown.

21 Conclusion: International recommendations were generated for the management of flaps in
22 head and neck radiotherapy. Considerable knowledge gaps hinder further consensus, in
23 particular with respect to tumor spread patterns.

24 Key words: head and neck, cancer, radiotherapy, postoperative, reconstructive surgery, flap,
25 consensus / recommendation

26 **Introduction**

27 For large head and neck tumors, reconstructive surgery is frequently performed using an
28 autologous flap, harvested from the patient donor site and transferred to the tumor bed to
29 compensate for the loss of substance [1–4]. Increasingly versatile flaps have aimed to achieve
30 high fidelity to the native tissues to improve functional outcomes and quality of life [5].

31 Target volumes have been extensively defined and evaluated for patients undergoing
32 definitive primary radiotherapy [6]. However, postoperative target volumes have been
33 described less extensively [7–11] and new developments in head and neck cancer surgery
34 have yet to be evaluated in terms of their consequences on the performance of poRT
35 [2,12,13]. The poRT clinical target volume (CTV of the primary resection site) is classically
36 defined to include the tissues that contain macroscopic or microscopic tumor at risk for tumor
37 recurrence. On the other hand, flaps are present in about half the patients (oral cavity and
38 oropharynx in particular) undergoing poRT (poRT)[14], and flaps result in substantial tissue
39 changes [11,15]. Additionally, several surgical reports have suggested that radiotherapy has
40 deleterious effects on flaps with respect to functional outcomes (dysphagia/swallowing,
41 speech, cosmesis, range of motion) [16–24]. Current radiation oncology literature lacks
42 recommendations for the delineation and management of poRT target volumes when there
43 is a flap in the tumor bed [24–29].

44 We assessed the current state of knowledge based on literature and expertise. Practice
45 patterns among the Groupe d’Oncologie Radiotherapie des Tumeurs de la tete Et du Cou
46 (GORTEC) were analyzed to develop an initial set of recommendations. Subsequently, these
47 proposals were circulated to an international reviewing group from HNCIG for validation and
48 endorsement. The goal was to develop an international consensus to aid clinical decision-
49 making and to identify areas of controversy and uncertainty related to postoperative
50 irradiation of flaps.

51

52 **Material and methods**

53 A stepwise consensus-building method was used [30,31](Figure 1). The GORTEC steering
54 group, defined by the GORTEC and French Head and Neck InterGroup (HNFIG) coordinator (JT,
55 FC) and composed of head and neck radiation oncologists (N=4), surgical oncologists (N=2)
56 and one radiologist, defined relevant questions based on a systematic review of the literature
57 (Figure 1). A search of MESH terms including “radiotherapy” and “flap” in title yielded 82

1 58 references from 1971 to 2021. After eliminating, based on a review of titles and abstracts,
2 59 non-head, and neck references (N= 41 (>80% breast)), references addressing salvage flap
3 60 surgery after prior radiotherapy (N= 25), and neoadjuvant radiotherapy and delayed
4 61 reconstruction (N= 5), there remained 15 articles. These included three case reports in English
5 62 or other language (N=1) (evidence-based grade C), five retrospective series of 13 to 100
6 63 patients [24,25,32–34] (grade C) and seven prospective series of 12 to 44 patients [33,35–40],
7 64 addressing flap changes (N=2) or functional and quality of life outcomes (N=5)(grade B).

8 65 As a first step, the GORTEC steering group designed a 59-item online questionnaire
9 66 (www.easy-crf.com/Delphi-Flap-RT). The questionnaire included numerous statements or
10 67 proposals, covering four major domains, to be agreed or disagreed with. The four domains
11 68 were: 1) identification of flaps on imaging for flap delineation, 2) understanding of the risk of
12 69 tumor relapse and tumor spread patterns and definition of target volumes, 3) functional
13 70 deterioration with respect to expectations of reconstructive surgery with a flap, and 4)
14 71 feasibility of dose painting using intensity modulated radiotherapy (IMRT) considering a need
15 72 to adapt poRT in the presence of flaps.

16 73 In the second step, a GORTEC rating group of 15 radiation oncologists from academic
17 74 university and general hospitals, comprehensive cancer centers and private clinics, with ≥ 10 -
18 75 year experience in head and neck cancers, rated all of the statements in two successive rounds
19 76 (Figure, Table 1). Each proposal was rated between 1 and 9 (1: disagree; 9: totally agree) in
20 77 rounds 1 and 2 (Table 1). They were informed of their scores and others between rounds 1
21 78 and 2. Items not reaching strong or relative agreement (defined in Table 1, requiring a median
22 79 score of $\geq 7/9$) following round 1 were submitted to the same panelists to be rated again in
23 80 light of the answers (quantitative feedback) and corresponding arguments (qualitative
24 81 feedback) of the other panelists (collected during round 2). Proposals not yielding strong or
25 82 relative agreement after round 2 were eliminated.

26 83 All items reaching strong or relative agreement following round 2 (Table 1) were then rated
27 84 by 30 international reviewers. This group was composed of radiation oncologists (N=26),
28 85 surgical oncologists (N=2) and medical oncologists (N=2), selected for their international
29 86 reputation for expertise in head and neck cancer management and leadership

30 87 Items were accepted when rated between 5 to 9 by 90% of the reviewer committee and these
31 88 constituted the final recommendations (Figure 1). Surgeons and medical oncologists reviewed
32 89 all of the statements related to combined modality treatments; they were invited to review

90 the statements from a multidisciplinary perspective and their responses were incorporated
91 and analyzed separately.

93 **Results**

94 After the two successive rounds, strong agreement, relative agreement, or no consensus was
95 achieved for 26, 9 and 24 items out of the initial 59 items, respectively (Table 2). Median scores
96 and final consensus categorizations are provided in table 2. In all, after external review, overall
97 consensus was only clearly achieved across of the four domains, with 11/15 items (73.3%)
98 achieving consensus on the risk of radiation-induced functional deterioration of flaps. In the
99 other domains, there was consensus achieved on specific items: 5/9 items (55.6%) on
100 feasibility of poRT dose-painting for flap avoidance; 7/17 (41.2%) items on flap definition; and
101 2/18 items (11.1%) on risk of tumor relapse and patterns of tumor spread in the presence of
102 a flap (Table 2). Among the items initially validated as achieving strong/relative consensus in
103 the rating group, those not achieving consensus in the third-round reviewing group (n=10)
104 were related to flap delineation (n=3) and tumor spread pattern (n=7).

105 Flap definition on imaging has hardly been addressed in the literature and is described with
106 grade C evidence at best [2,14,15,25,41]. Still, at final review, flap definition was able to
107 achieve strong agreement for 6 items (Table 2). The final recommendations were as follows:
108 (1) surgeons should accurately describe the flap with respect to the native anatomy following
109 tumor resection in standardized operating reports; (2) surgeons should also report whether
110 clips were used in the tumor bed point to areas of dubious R0 or R1 resection or hemostasis;
111 (3) clips should be placed in a standardized manner and regardless of the negligible artifacts
112 that they produce, which do not interfere with delineation and dose calculation; (4) the
113 planning CT should be contrast-enhanced for better flap visualization and to help pick up
114 ignored residual tumor or early relapse.

115 Ten items were controversial: 7 after the second round and 3 after external review (Table 2).
116 Experts disagreed on the degree of difficulty in identifying flap contours or components on a
117 planning CT as well as identification of the junctional area [15]. More importantly, no
118 consensus was reached within the committee as to how the flap should be delineated (Table
119 2). Uncertainties remained on whether to place clips at the flap-tissue junction [42], the
120 usefulness of contrast enhancement to distinguish the vascular anastomosis, and acquisition

121 of magnetic resonance imaging to visualize the flap versus referring to a surgeon for
122 delineation.

123 Tumor risk assessment with respect to the installed flap has only been addressed in a few
124 grade C publications [42–44]. Only 2 items that achieved strong agreement after the rating
125 phase were validated by the reviewing group (Table 2) stating that: (1) clinicians should be
126 aware that the flap-tissue junction is at higher risk of tumor recurrence compared to other
127 areas of the flap and (2) the dose delivered to the junctional area should be the same as the
128 dose delivered to the primary high-risk CTV, if the final resection margin is involved (R2), close
129 (R1) or if there is ambiguity about complete clearance (Table 2). Nine items did not achieve
130 consensus after the rating phase and were not circulated to the review group. The rating
131 group disagreed on enlarged expansions around the preoperative GTV to compensate for
132 delineation uncertainties. The rating group was uncertain about the likelihood of microscopic
133 tumor spread from the junctional area toward the “mucosal or cutaneous” flap surface and
134 the impact of histology or tumor primary site on risk of recurrence. No consensus was reached
135 as to whether the “junctional area” should be considered to be 10 mm or more [41]. No
136 consensus was reached as to whether the body of the flap should be included in the low-risk
137 area to decrease morbidity, or if it should be included in the high-risk area to compensate for
138 delineation uncertainties. For pedicled flaps, no consensus was reached as to whether the
139 vascular pedicle should be included in the CTV. For free flaps, it was uncertain as to whether
140 vascular anastomosis is a means of tumor dissemination.

141 Interestingly, 7 items related to tumor spread patterns into flaps and flap definition as a CTV
142 or organ at risk, previously achieving strong/relative agreement after round 2, were not
143 supported by the international review group (Figure 1, Table 2). The review group disagreed
144 on the need for systematic coregistration of the preoperative imaging with the postoperative
145 CT scan to define the postoperative CTV, and on the inclusion in the CTV of "direct"
146 postoperative modifications (edema, hematoma, lymphocele) due to flap surgery. The review
147 group did not agree on the likelihood of microscopic tumor spread patterns from the
148 junctional area toward deep native tissues or whether tumor spread pattern was dependent
149 on flap components (mucosa / skin, fat, muscle / fascia, bone) [15]. The review group also
150 would not endorse consensus on a 6 mm size to define the junction area [44]. Similarly, no
151 consensus was reached as to whether very large flaps and vascular anastomosis should be

152 included in the CTV, nor was consensus reached as to which dose should be delivered to the
1 153 junction area if the resection is R0.
2
3
4 154 A functional deleterious impact of radiotherapy on flaps has been repeatedly suggested in the
5
6 155 surgical literature (grade B or C) but has not been formally assessed using controlled studies
7
8 156 [24,35]. Strong agreement was achieved for 9 items and relative agreement for 2 items (Table
9
10 157 2). The rating group did not reach consensus on differential effects of poRT on vascular
11
12 158 anastomosis from free vs pedicled flap, the impact of flap atrophy on functional deterioration
13
14 159 or the need for surgical overcompensation. These items were therefore not submitted to the
15
16 160 review group. There was consensus after the rating phase that flap necrosis could not result
17
18 161 from damage of vascular anastomosis or thrombosis, but rather would occur in the early
19
20 162 postoperative period (caused by the vessel quality, morbidity, or technical procedure)
21
22 163 regardless of poRT. However, the international recommendation was to consider that poRT
23
24 164 altered soft-tissue flap versatility and its functional results (swallowing, phonation) as well as
25
26 165 increased the risk of osteoradionecrosis in bone flaps. The final recommendation stated that
27
28 166 flap fibrosis or (fat) atrophy occurred spontaneously but could increase with poRT and with
29
30 167 dose.
31
32 168 Feasibility of complex IMRT modulation for flap avoidance was controversial. The rating group
33
34 169 did not achieve consensus on the risk of osteoradionecrosis in the presence of metal in the
35
36 170 poRT field, or on the need to avoid irradiating the titanium plate fixing the flap and whether
37
38 171 such materials should be substituted. Thus, these items were not submitted to the review
39
40 172 group and no final recommendation can be made about them. In the end, strong and relative
41
42 173 agreement was achieved for 3 and 2 items, respectively, on international review (Table 2). The
43
44 174 final, internationally validated recommendations were (1) to use steep gradients to achieve
45
46 175 elimination of maximum dose (hot spots) to a delineated vascular pedicle if feasible but (2)
47
48 176 that avoidance might not be achievable in thin flaps and (3) the flap mean dose or maximum
49
50 177 dose be reduced if necessary, to limit the risks of fatty atrophy, muscle fibrosis or
51
52 178 osteoradionecrosis.
53
54 179 One should note that there was substantial variability between the international reviewers
55
56 180 for 11 items which had achieved strong/relative consensus in the rating committee but were
57
58 181 rejected by the review group (Figure 2). There were also trends by country.
59
60 182
61
62 183
63
64
65

184 **Discussion**

1
2 185 In the past, experience with flaps and radiotherapy was usually limited to salvage surgery
3
4 186 occurring in irradiated tissues. With increasing surgical expertise, immediate rather than
5
6 187 delayed reconstruction has become standard. Flaps have been used in primary reconstructive
7
8 188 head and neck surgery increasingly over the last 2 decades although the pioneering works
9
10 189 date to the 70's [1,4,19,20,45,46]. Because tumors that require a flap are usually large and of
11
12 190 advanced T stage [47], they often require poRT. In our initial systemic review, we found
13
14 191 abundant surgical grade B-C literature suggesting radiation-induced flap changes [34,38,39]
15
16 192 and deteriorated functional outcomes [24,33,35–40]. Additional anecdotal (grade C) case
17
18 193 studies reported flap loss after poRT. However, no references to flaps appear in the latest
19
20 194 postoperative radiotherapy recommendations [11,47]. This reflects heterogeneity in practice
21
22 195 but also that the management of flaps during radiotherapy is an area of high ambiguity [2].
23 196 Our stepwise consensus-building approach among an international community of head and
24
25 197 neck experts, mostly radiation oncologists, was able to generate novel recommendations
26
27 198 regarding the importance of surgeons reporting on clip placement and operating procedures
28
29 199 more accurately. However, due to continuing knowledge gaps concerning flap definition on
30
31 200 imaging and more importantly flaps as possible routes for tumor dissemination, there were
32
33 201 major uncertainties that translated into significant variability at the international reviewing
34
35 202 phase.
36
37 203 Our international panel could not agree on in-flap tumor spread patterns and could not
38
39 204 determine whether a flap should be considered as part of the clinical target volume. There
40
41 205 was no agreement on risk based on tumor site, tumor histology, or flap components as factors
42
43 206 influencing tumor spread patterns. There was also lack of agreement on whether the whole
44
45 207 flap (+/- its vascular anastomosis) should be included or only its area next to the flap-tissue
46
47 208 junction as suggested by one team based on their practice rather than evidence [42–44].
48
49 209 There is concern about irradiation of large pedicled flaps, such as pectoralis major flaps, as
50
51 210 including the whole flap in the CTV can inflate irradiated normal tissue volumes significantly
52
53 211 and result in more toxicities [25].
54
55 212 The international group agreed on the concern about radiation-induced fibrosis and atrophy
56
57 213 which might affect function. Therapeutic recommendations were to achieve flap and vascular
58
59 214 pedicle dose avoidance through steep gradients potentially using complex fluence
60
61 215 modulation. The surgical literature mostly reports small surgical series of fibrosis and atrophy.

216 As the true prevalence of flap atrophy of large fatty flaps is unknown, this is an area requiring
1 further future assessment. There is limited but higher-quality literature (grade B-C) concerning
2 217 functional outcomes following flap irradiation, which underscores the importance of defining
3 218 the volumes and doses given to these flaps to better study their effects. There remains a need
4 219 for better reports of literature and experience-based knowledge of functional outcomes
5 220 following flap irradiation.
6 221

11 222 Items regarding the management of metal materials for bone flaps were controversial from
12 scratch and could not reach the review phase.
13 223

15 224 An important factor in variability, and a potential limitation of this process, is shown by the 11
16 225 items that passed the initial rating phase but were rejected by the international group. While
17 226 in part due to a lack of published evidence or data, there may also be variable experience with
18 227 postoperative radiotherapy across countries, or even individual centers. There may be various
19 228 strategies regarding the use of surgery followed by radiotherapy or upfront radiotherapy and
20 229 consequently the management of flaps [48].
21 230

29 231 **Conclusion**

31 232 The major internationally validated consensus statements were that the flap-tissue junction
32 233 should be considered at higher risk of tumor spread compared to other areas of the flap and
33 234 that postoperative planning should be based on a contrast-enhanced CT. Surgeons should
34 235 report the placement of flaps more accurately and consider clip placement to guide
35 236 radiotherapy planning. It was also recommended to consider the risks of radiation-induced
36 237 atrophy, fibrosis, and osteoradionecrosis and limit the maximum and mean doses during the
37 238 radiotherapy planning process. There remain substantial knowledge gaps and as result, large
38 239 areas of international variability. Patterns of tumor spread, and the results of dose-avoidance
39 240 should be analyzed prospectively with assessment of functional outcomes and quality of life.
40 241
41 242

243 **References**

- 1
2 244 [1] Urken ML. Advances in head and neck reconstruction. *The Laryngoscope*
3 245 2003;113:1473–6. <https://doi.org/10.1097/00005537-200309000-00008>.
- 4 246 [2] Thariat J, Leleu T, Micault E, Gery B, Bastit V, Jeanne C, et al. [Ten years of advances in
5 247 head and neck surgery, how does this influence postoperative radiotherapy?]. *Bull Cancer*
6 248 (Paris) 2020;107:823–9. <https://doi.org/10.1016/j.bulcan.2020.04.011>.
- 7 249 [3] Cormack GC, Lamberty BG. A classification of fascio-cutaneous flaps according to their
8 250 patterns of vascularisation. *Br J Plast Surg* 1984;37:80–7. [https://doi.org/10.1016/0007-1226\(84\)90049-3](https://doi.org/10.1016/0007-1226(84)90049-3).
- 9 251
10 252 [4] Lamberty BG, Cormack GC. Progress in flap surgery: greater anatomical understanding
11 253 and increased sophistication in application. *World J Surg* 1990;14:776–85.
12 254 <https://doi.org/10.1007/BF01670524>.
- 13 255 [5] Bozec A, Demez P, Gal J, Chamorey E, Louis M-Y, Blanchard D, et al. Long-term quality
14 256 of life and psycho-social outcomes after oropharyngeal cancer surgery and radial forearm
15 257 free-flap reconstruction: A GETTEC prospective multicentric study. *Surg Oncol* 2018;27:23–30.
16 258 <https://doi.org/10.1016/j.suronc.2017.11.005>.
- 17 259 [6] Grégoire V, Evans M, Le Q-T, Bourhis J, Budach V, Chen A, et al. Delineation of the
18 260 primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal
19 261 and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC,
20 262 HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA,
21 263 SRO, SSHNO, TROG consensus guidelines. *Radiother Oncol J Eur Soc Ther Radiol Oncol*
22 264 2018;126:3–24. <https://doi.org/10.1016/j.radonc.2017.10.016>.
- 23 265 [7] Chao KSC, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of failure in
24 266 patients receiving definitive and postoperative IMRT for head-and-neck cancer. *Int J Radiat*
25 267 *Oncol Biol Phys* 2003;55:312–21. [https://doi.org/10.1016/s0360-3016\(02\)03940-8](https://doi.org/10.1016/s0360-3016(02)03940-8).
- 26 268 [8] Grégoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the
27 269 nodal CTV in the node-positive and the post-operative neck. *Radiother Oncol J Eur Soc Ther*
28 270 *Radiol Oncol* 2006;79:15–20. <https://doi.org/10.1016/j.radonc.2006.03.009>.
- 29 271 [9] Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, et al. CT-based
30 272 delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA,
31 273 EORTC, GORTEC, NCIC, RTOG consensus guidelines. *Radiother Oncol J Eur Soc Ther Radiol*
32 274 *Oncol* 2003;69:227–36. <https://doi.org/10.1016/j.radonc.2003.09.011>.
- 33 275 [10] Cho Y, Yoon HI, Lee IJ, Kim JW, Lee CG, Choi EC, et al. Patterns of local recurrence after
34 276 curative resection and reconstruction for oropharyngeal and oral cancers: Implications for
35 277 postoperative radiotherapy target volumes. *Head Neck* 2019;41:3916–23.
36 278 <https://doi.org/10.1002/hed.25928>.
- 37 279 [11] Evans M, Beasley M. Target delineation for postoperative treatment of head and neck
38 280 cancer. *Oral Oncol* 2018;86:288–95. <https://doi.org/10.1016/j.oraloncology.2018.08.011>.
- 39 281 [12] Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining
40 282 risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent
41 283 postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
42 284 *Head Neck* 2005;27:843–50. <https://doi.org/10.1002/hed.20279>.
- 43 285 [13] Bernier J, Dommenege C, Ozsahin M, Matuszewska K, Lefèbvre J-L, Greiner RH, et al.
44 286 Postoperative irradiation with or without concomitant chemotherapy for locally advanced
45 287 head and neck cancer. *N Engl J Med* 2004;350:1945–52.
46 288 <https://doi.org/10.1056/NEJMoa032641>.
- 47 289 [14] Racadot S, Vérillaud B, Serre A-A, Le Guevelou J, Guzène L, Laude C, et al. [Impact of

290 reconstructive or minimal invasive surgery on the assessment of current definitions of
1 291 postoperative clinical target volume for head and neck cancers]. *Cancer Radiother J Soc*
2 292 *Francaise Radiother Oncol* 2020;24:649–57. <https://doi.org/10.1016/j.canrad.2020.05.012>.
3 293 [15] Le Guevelou J, Bastit V, Marcy PY, Lasne-Cardon A, Guzène L, Gerard M, et al. Flap
4 294 delineation guidelines in postoperative head and neck radiation therapy for head and neck
5 295 cancers. *Radiother Oncol J Eur Soc Ther Radiol Oncol* 2020;151:256–65.
6 296 <https://doi.org/10.1016/j.radonc.2020.08.025>.
7 297 [16] Yi CR, Jeong WS, Oh TS, Koh KS, Choi J-W. Analysis of Speech and Functional Outcomes
8 298 in Tongue Reconstruction after Hemiglossectomy. *J Reconstr Microsurg* 2020;36:507–13.
9 299 <https://doi.org/10.1055/s-0040-1709493>.
10 300 [17] Pierre CS, Dassonville O, Chamorey E, Poissonnet G, Riss J-C, Ettaiche M, et al. Long-
11 301 term functional outcomes and quality of life after oncologic surgery and microvascular
12 302 reconstruction in patients with oral or oropharyngeal cancer. *Acta Otolaryngol (Stockh)*
13 303 2014;134:1086–93. <https://doi.org/10.3109/00016489.2014.913809>.
14 304 [18] Rihani J, Lee MR, Lee T, Ducic Y. Flap selection and functional outcomes in total
15 305 glossectomy with laryngeal preservation. *Otolaryngol--Head Neck Surg Off J Am Acad*
16 306 *Otolaryngol-Head Neck Surg* 2013;149:547–53. <https://doi.org/10.1177/0194599813498063>.
17 307 [19] Bozec A, Poissonnet G, Chamorey E, Laout C, Vallicioni J, Demard F, et al. Radical
18 308 ablative surgery and radial forearm free flap (RFFF) reconstruction for patients with oral or
19 309 oropharyngeal cancer: postoperative outcomes and oncologic and functional results. *Acta*
20 310 *Otolaryngol (Stockh)* 2009;129:681–7. <https://doi.org/10.1080/00016480802369260>.
21 311 [20] Bozec A, Poissonnet G, Chamorey E, Casanova C, Vallicioni J, Demard F, et al. Free-flap
22 312 head and neck reconstruction and quality of life: a 2-year prospective study. *The Laryngoscope*
23 313 2008;118:874–80. <https://doi.org/10.1097/MLG.0b013e3181644abd>.
24 314 [21] Bozec A, Poissonnet G, Chamorey E, Casanova C, Laout C, Vallicioni J, et al. Quality of
25 315 life after oral and oropharyngeal reconstruction with a radial forearm free flap: prospective
26 316 study. *J Otolaryngol - Head Neck Surg J Oto-Rhino-Laryngol Chir Cervico-Faciale* 2009;38:401–
27 317 8.
28 318 [22] Zhang X, Li M-J, Fang Q-G, Sun C-F. A comparison between the pectoralis major
29 319 myocutaneous flap and the free anterolateral thigh perforator flap for reconstruction in head
30 320 and neck cancer patients: assessment of the quality of life. *J Craniofac Surg* 2014;25:868–71.
31 321 <https://doi.org/10.1097/SCS.0000000000000443>.
32 322 [23] van Hinte G, Wetzels J-WGH, Merckx MAW, de Haan AFJ, Koole R, Speksnijder CM.
33 323 Factors influencing neck and shoulder function after oral oncology treatment: a five-year
34 324 prospective cohort study in 113 patients. *Support Care Cancer Off J Multinatl Assoc Support*
35 325 *Care Cancer* 2019;27:2553–60. <https://doi.org/10.1007/s00520-018-4534-1>.
36 326 [24] Shin YS, Koh YW, Kim S-H, Jeong JH, Ahn S, Hong HJ, et al. Radiotherapy deteriorates
37 327 postoperative functional outcome after partial glossectomy with free flap reconstruction. *J*
38 328 *Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg* 2012;70:216–20.
39 329 <https://doi.org/10.1016/j.joms.2011.04.014>.
40 330 [25] Gérard M, Le Guevelou J, Jacksic N, Lequesne J, Bastit V, Géry B, et al. Postoperative
41 331 radiotherapy after flap reconstructive surgery in patients with head and neck cancer: A
42 332 retrospective monocentric study with flap delineation to assess toxicity and relapse. *Cancer*
43 333 *Radiother J Soc Francaise Radiother Oncol* 2020;24:851–9.
44 334 <https://doi.org/10.1016/j.canrad.2020.06.024>.
45 335 [26] Las DE, de Jong T, Zuidam JM, Verweij NM, Hovius SER, Mureau MAM. Identification
46 336 of independent risk factors for flap failure: A retrospective analysis of 1530 free flaps for
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

337 breast, head and neck and extremity reconstruction. *J Plast Reconstr Aesthetic Surg JPRAS*
1 338 2016;69:894–906. <https://doi.org/10.1016/j.bjps.2016.02.001>.

2 339 [27] Ooishi M, Motegi A, Kawashima M, Arahira S, Zenda S, Nakamura N, et al. Patterns of
3 340 failure after postoperative intensity-modulated radiotherapy for locally advanced and
4 341 recurrent head and neck cancer. *Jpn J Clin Oncol* 2016;46:919–27.
5 342 <https://doi.org/10.1093/jjco/hyw095>.

6 343 [28] Halle M, Eriksson BO, Docherty Skogh A-C, Sommar P, Hammarstedt L, Gahm C.
7 344 Improved Head and Neck Free Flap Outcome-Effects of a Treatment Protocol Adjustment from
8 345 Pre- to Postoperative Radiotherapy. *Plast Reconstr Surg Glob Open* 2017;5:e1253.
9 346 <https://doi.org/10.1097/GOX.0000000000001253>.

10 347 [29] Choi S, Schwartz DL, Farwell DG, Austin-Seymour M, Futran N. Radiation therapy does
11 348 not impact local complication rates after free flap reconstruction for head and neck cancer.
12 349 *Arch Otolaryngol Head Neck Surg* 2004;130:1308–12.
13 350 <https://doi.org/10.1001/archotol.130.11.1308>.

14 351 [30] Jones J, Hunter D. Consensus methods for medical and health services research. *BMJ*
15 352 1995;311:376–80. <https://doi.org/10.1136/bmj.311.7001.376>.

16 353 [31] French Haute autorité de santé. Elaboration de recommandation de bonne pratique -
17 354 Recommandations par consensus formalisé 2010.

18 355 [32] Tai H-C, Hsieh C-H, Chao KSC, Liu S-H, Leu Y-S, Chang Y-F, et al. Comparison of
19 356 radiotherapy strategies for locally advanced hypopharyngeal cancer after resection and
20 357 ileocolic flap reconstruction. *Acta Otolaryngol (Stockh)* 2009;129:311–7.
21 358 <https://doi.org/10.1080/00016480802163366>.

22 359 [33] Haymerle G, Enzenhofer E, Lechner W, Stock M, Schratte-Sehn A, Vyskocil E, et al. The
23 360 effect of adjuvant radiotherapy on radial forearm free flap volume after soft palate
24 361 reconstruction in 13 patients. *Clin Otolaryngol Off J ENT-UK Off J Neth Soc Oto-Rhino-Laryngol*
25 362 *Cervico-Facial Surg* 2018;43:742–5. <https://doi.org/10.1111/coa.13042>.

26 363 [34] Yamazaki M, Suzuki T, Hiraga C, Yoshida Y, Baba A, Saitou H, et al. Effect of
27 364 postoperative radiotherapy for free flap volume changing after tongue reconstruction. *Oral*
28 365 *Radiol* 2020. <https://doi.org/10.1007/s11282-020-00489-0>.

29 366 [35] Winter SCA, Cassell O, Corbridge RJ, Goodacre T, Cox GJ. Quality of life following
30 367 resection, free flap reconstruction and postoperative external beam radiotherapy for
31 368 squamous cell carcinoma of the base of tongue. *Clin Otolaryngol Allied Sci* 2004;29:274–8.
32 369 <https://doi.org/10.1111/j.1365-2273.2004.00812.x>.

33 370 [36] Leu Y-S, Hsiao H-T, Chang Y-C, Yang C-C, Lee J-C, Chen Y-J, et al. Ileocolic free flap
34 371 reconstruction, concomitant chemotherapy and radiotherapy and assessment of speech and
35 372 swallowing function during management of advanced cancer of the larynx and hypopharynx:
36 373 preliminary report. *Acta Otolaryngol (Stockh)* 2005;125:642–6.
37 374 <https://doi.org/10.1080/00016480510027457>.

38 375 [37] Airoidi M, Garzaro M, Raimondo L, Pecorari G, Giordano C, Varetto A, et al. Functional
39 376 and psychological evaluation after flap reconstruction plus radiotherapy in oral cancer. *Head*
40 377 *Neck* 2011;33:458–68. <https://doi.org/10.1002/hed.21471>.

41 378 [38] Higgins KM, Erovcic BM, Ravi A, Yeung R, Lee JW, Yao C, et al. Volumetric changes of the
42 379 anterolateral thigh free flap following adjuvant radiotherapy in total parotidectomy
43 380 reconstruction. *The Laryngoscope* 2012;122:767–72. <https://doi.org/10.1002/lary.22509>.

44 381 [39] Tarsitano A, Battaglia S, Cipriani R, Marchetti C. Microvascular reconstruction of the
45 382 tongue using a free anterolateral thigh flap: Three-dimensional evaluation of volume loss after
46 383 radiotherapy. *J Cranio-Maxillo-Fac Surg Off Publ Eur Assoc Cranio-Maxillo-Fac Surg*
47 384
48 385
49 386
50 387
51 388
52 389
53 390
54 391
55 392
56 393
57 394
58 395
59 396
60 397
61 398
62 399
63 400
64 401
65 402

384 2016;44:1287–91. <https://doi.org/10.1016/j.jcms.2016.04.031>.

1 385 [40] Lilja M, Markkanen-Leppänen M, Viitasalo S, Saarilahti K, Lindford A, Lassus P, et al.
2 386 Olfactory and gustatory functions after free flap reconstruction and radiotherapy for oral and
3 387 pharyngeal cancer: a prospective follow-up study. *Eur Arch Oto-Rhino-Laryngol Off J Eur Fed*
4 388 *Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg*
5 389 2018;275:959–66. <https://doi.org/10.1007/s00405-018-4883-x>.

6 390 [41] Fleury B, Thariat J, Barnoud R, Buiret G, Lebreton F, Bancel B, et al. [Microscopic
7 391 extensions of head and neck squamous cell carcinomas: impact for clinical target volume
8 392 definition]. *Cancer Radiother J Soc Francaise Radiother Oncol* 2014;18:666–71.
9 393 <https://doi.org/10.1016/j.canrad.2014.04.006>.

10 394 [42] Bittermann G, Wiedenmann N, Bunea A, Schwarz SJ, Grosu A-L, Schmelzeisen R, et al.
11 395 Clipping of tumour resection margins allows accurate target volume delineation in head and
12 396 neck cancer adjuvant radiation therapy. *Radiother Oncol J Eur Soc Ther Radiol Oncol*
13 397 2015;116:82–6. <https://doi.org/10.1016/j.radonc.2015.04.025>.

14 398 [43] Bittermann G, Voss P, Duttenhoefer F, Zimmerer R, Vach K, Metzger MC. The validity
15 399 of surgical clips as radiographic markers for the tumour resection cavity in head and neck
16 400 cancer treatment. *J Cranio-Maxillo-Fac Surg Off Publ Eur Assoc Cranio-Maxillo-Fac Surg*
17 401 2015;43:758–62. <https://doi.org/10.1016/j.jcms.2015.04.005>.

18 402 [44] Bittermann G, Wiedenmann N, Voss P, Zimmerer R, Duttenhoefer F, Metzger MC.
19 403 Marking of tumor resection borders for improved radiation planning facilitates reduction of
20 404 radiation dose to free flap reconstruction in head and neck cancer surgery. *J Cranio-Maxillo-*
21 405 *Fac Surg Off Publ Eur Assoc Cranio-Maxillo-Fac Surg* 2015;43:567–73.
22 406 <https://doi.org/10.1016/j.jcms.2015.02.021>.

23 407 [45] Jose B, Banis J, Flynn M, Lindberg R, Spanos WJ, Paris K, et al. Irradiation and free tissue
24 408 transfer in head and neck cancer. *Head Neck* 1991;13:213–6.
25 409 <https://doi.org/10.1002/hed.2880130308>.

26 410 [46] Nakamizo M, Yokoshima K, Yagi T. Use of free flaps for reconstruction in head and neck
27 411 surgery: a retrospective study of 182 cases. *Auris Nasus Larynx* 2004;31:269–73.
28 412 <https://doi.org/10.1016/j.anl.2004.03.003>.

29 413 [47] Margalit DN, Sacco AG, Cooper JS, Ridge JA, Bakst RL, Beadle BM, et al. Systematic
30 414 review of postoperative therapy for resected squamous cell carcinoma of the head and neck:
31 415 Executive summary of the American Radium Society appropriate use criteria. *Head Neck*
32 416 2021;43:367–91. <https://doi.org/10.1002/hed.26490>.

33 417 [48] Culié D, Garrel R, Viotti J, Schiappa R, Chamorey E, Fakhry N, et al. Impact of HPV-
34 418 associated p16-expression and other clinical factors on therapeutic decision-making in
35 419 patients with oropharyngeal cancer: A GETTEC multicentric study. *Eur J Surg Oncol J Eur Soc*
36 420 *Surg Oncol Br Assoc Surg Oncol* 2018;44:1908–13.
37 421 <https://doi.org/10.1016/j.ejso.2018.05.022>.

38 422
39 423
40 424
41 425
42 426
43 427
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

60
61
62
63
64
65

428 **Figures and Tables legend**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

429 Figure 1 **consensus methodology** (adapted from the French Health authorities
430 'recommendation, https://www.has-sante.fr/upload/docs/application/pdf/2011-06/guideline_by_formal_consensus_quick_methodology_guide_110531.pdf)

431
432 GORTEC Groupe d'Oncologie Radiotherapie des tumeurs de la Tete Et du Cou, HNFIC Head
433 and Neck French InterGroup, international Head and Neck Cancer experts.

434
435 Figure 2 **Analysis of items** that passed the initial rating phase but were rejected by the
436 international review group, with voting by country.

437
438 Table 1 **Criteria for acceptance of proposals** based on median value and distribution of
439 ratings.

440
441 Table 2 **Proposals submitted and rated** across successive rounds.

Table 1: Criteria for acceptance of proposals based on median value and distribution of ratings.

Proposal evaluation		Median value	Distribution of responses
Appropriate	Strong agreement	≥ 7	All between [7- 9]
	Relative agreement	≥ 7	All between [5- 9]
Inappropriate	Strong agreement	≤ 3	All between [1- 3]
	Relative agreement	≤ 3.5	All between [1- 5]
Uncertain	Indecision	$4 \leq \text{median} \leq 6,5$	All between [1-9]
	Lack of consensus	All others	

For a group of more than 15 experts, analysis in the second round allowed exclusion of a missing value or a value opposite to that dominant group.

Table 2: Proposals submitted and rated across successive rounds.

Item	Proposals established by a GORTEC steering committee and present at:	GORTEC Rating Committee		External Review group
		Round 1	Round 2	Round 3
Flap Delineation				
1	It is not well defined how to identify the flap contours on a planning CT	NC [6]	RA [7]	NC
2	It is difficult to identify the components of a flap according to their density on the planning CT	NC [7]	SA [7]	NC
3	The junction area (as defined by Bittermann) is difficult to define on a postoperative CT scan	NC [7]	SA [8]	NC
4	Surgeons should report on the position of the flap with respect to the native anatomy following tumor resection in their operating report	NC [8]	SA [8]	FR
5	It is important that surgeons report whether they used clips for hemostasis in the flap area	NC [5]	RA [7]	FR
6	It is important that surgeons report on using clips to define areas of questionable (dubious R0 or R1) resection	NC [5]	SA [8]	FR
7	The placement of clips around the tumor bed should be standardized between surgeons and described in the operating report	NC [8]	SA [8]	FR
8	The use of clips does not induce significant artifacts and should not interfere with delineation and dose calculation	NC [6.5]	SA [8]	FR
9	It is important that the planning CT be contrast enhanced to better visualize the flap	NC [7.5]	SA [8]	FR
10	It is important that the planning CT be contrast enhanced so as not to ignore an early evolution or a macroscopic postoperative tumor residue	SA [9]		FR
11	It is important to contour the flap	NC [5]	NC [7]	
12	It is not necessary to contour the flap because it is systematically positioned in an area to be irradiated (in the primary CTV T or in the prophylactic lymph node volumes N)	NC [5]	NC [3]	
13	It is important for surgeons to describe in their operating report whether they are using clips to show the junction area between the flap and native tissues remaining after tumor resection	NC [5]	NC [7]	
14	It is important to inject the planning CT to visualize the vascular pedicle	NC [7]	NC [7]	

15	Postoperative MRI might be helpful to improve visualization of the flap	NC [6]	NC [6]	
16	The recommendations for delineating CTVs are applicable whether there is a flap in the operating area or not (recommendations of Evans 2018 postoperatively)	NC [6]	NC [5]	
17	It is essential to carry out the delineation in the presence of the surgeon	NC [4]	NC [3]	
Tumor spread pattern in a flap				
18	Coregistration of the preoperative imaging with the postoperative CT scan should be performed systematically to define the postoperative CTV	NC [8]	RA [8]	NC
19	Coregistration uncertainties (of the preoperative imaging with postoperative planning CT) should be compensated by expanding larger margins (than recommended for postoperative radiotherapy) around the preoperative GTV	NC [6]	NC [5]	
20	"Direct" postoperative modifications (edema, hematoma, lymphocele) of the flap should be included in the CTV	NC [7]	SA [7]	NC
21	The risk of microscopic tumor spread is centrifugal from the junction area to the depth of the remaining native tissues	NC [7]	SA [8]	NC
22	The risk of spreading microscopic disease is centrifugal from the junction area to the "mucous or cutaneous" surface of the flap	NC [4.5]	NC [5]	
23	The risk of microscopic diffusion into the flap may vary depending on the histology (squamous cell carcinoma and variants, adenoid cystic carcinoma, adenocarcinoma...)	NC [5]	NC [6]	
24	The risk of microscopic diffusion into the flap may vary depending to the tumor location (parotid vs pharynx vs sinus)	NC [6.5]	NC [6]	
25	The junction area between the native tissues (remaining after tumor resection) and the deep part of the flap is an area at higher risk of cancer	SA [8]		FR
26	The junction area is an area of the order of 6 mm thick in the depth of the flap as described by Bittermann (2015)	NC [6]	RA [7]	NC
27	The junction area at risk is about 10 mm thick in the depth of the flap	NC [5.5]	NC [5]	
28	The junction area varies in thickness depending on the nature of the components of the flap (mucosa / skin, fat, muscle / fascia, bone)	NC [7]	SA [7]	NC
29	The body of the flap (including all the rest of the flap beyond the junction area) should be irradiated entirely in the low-risk area	NC [4]	NC [3]	


30	When the flap is very large, some of the flap body may not be included in the low-risk area	NC [6.5]	SA [8]	NC
31	The delineation uncertainties are so great in the postoperative situation that it is better to irradiate wide even if it means including the entire flap	NC [4.5]	NC [7]	
32	For pedicled flaps, it is not useful to include the vascular pedicle in the CTV. Its tumor colonization is unlikely, and its distal part is far from the operating bed of the primary patient	NC [4.5]	NC [7]	
33	For free flaps, vascular anastomosis is not a way of tumor dissemination	NC [5]	NC [7]	
34	The dose level delivered to the junction area corresponds to primary low-risk CTV if the resection is R0	NC [7.5]	RA [8]	NC
35	The dose level delivered to the junction area corresponds to primary high-risk CTV if the final quality of the resection is dubious R0 or R1 or R2	SA [8]		FR
Functional flap outcomes				
36	Flap necrosis occurs in early postoperative (vessel quality, morbidity, technical procedure) and radiotherapy does not induce any specific risk	NC [7]	SA [8]	FR
37	Irradiation of the vascular pedicle of a flap induces a risk of necrosis of the flap that is negligible (=unlikely) (strong agreement)	NC [7]	SA [8]	FR
38	The dose received at the vascular anastomosis is not correlated with an increased risk of vascular thrombosis	NC [7]	RA [8]	FR
39	Irradiation of the vascular pedicle from a free flap is at higher risk of necrosis than irradiation of a vascular pedicle from a pedicled flap (no consensus)	NC [5]	NC [5]	
40	Radiotherapy alters the flexibility of the flap	NC [7]	SA [8]	FR
41	Radiotherapy can alter the functional results (swallowing, phonation) of the flap	NC [7]	SA [7]	FR
42	Irradiation of a bone flap is at risk of radionecrosis of the flap	NC [7]	SA [8]	FR
43	Atrophy of the fat flaps is possible spontaneously even in the absence of radiotherapy	NC [7]	SA [8]	FR
44	The risk of atrophy of the flap fat increases with radiotherapy	NC [8]	SA [8]	FR
45	Flap fat atrophy is associated with deterioration of functional results	NC [5.5]	NC [5]	
46	Flap fat atrophy MUST BE anticipated by surgeons by overcompensating tissue / flap thickness	NC [7]	NC [7]	
47	The radiation-induced atrophy of the fatty component of the flaps is related to the dose received	NC [5]	NC [7]	
48	Fibrosis changes of flaps are possible spontaneously even in the absence of radiotherapy	NC [6]	RA [7]	FR

49	Fibrosis of the muscle flap component can be favored by radiotherapy (significantly more than surgery alone)	NC [7]	SA [7]	FR
50	Radiation-induced flap fibrosis increases with dose	NC [7]	SA [7]	FR
Technical IMRT feasibility (dose painting for structure avoidance)				
51	For thin flap, it may not be possible to achieve sufficiently steep gradients to spare the flap of the part	NC [7.5]	SA [8]	FR
52	Limiting the average dose to the flap could limit the risk for fatty atrophy and muscle fibrosis	NC [6]	RA [7]	FR
53	Limiting the average dose to the bone of the flap could limit the risk for flap osteoradionecrosis	NC [7]	RA [7]	FR
54	Limiting the maximum dose to the bone flap could limit the risk for osteoradionecrosis	NC [8]	SA [8]	FR
55	In the case of a bone flap, the presence of titanium, or other metal, in the irradiation area induces an increased risk of osteoradionecrosis	NC [7.5]	NC [6]	
56	In the case of a bone flap, avoid irradiating the titanium plate fixing the flap allows to reduce the risk of osteoradionecrosis	NC [4.5]	NC [3]	
57	In the case of a bone flap, titanium-type materials must be substituted to reduce the risk of osteoradionecrosis	NC [4.5]	NC [5]	
58	Limiting the maximum dose (hot spots) to the vascular pedicle seems feasible technically if the pedicle is delineated	NC [7]	SA [7]	FR
59	Limiting the maximum dose (hot spots) to the vascular pedicle would reduce the risk of necrosis of the flap	NC [5]	NC [6]	

Legend: SA strong agreement, RA relative agreement, NC no consensus, FR final recommendation; GORTEC steering committee and GORTEC rating committee are independent; median is indicated between brackets (median = 7-9 is required but ≥ 2 eliminating grades qualify items as NC for the first two rounds).

Figure 1: consensus methodology

(adapted from the French Health authorities 'recommendation, https://www.has-sante.fr/upload/docs/application/pdf/2011-06/guideline_by_formal_consensus_quick_methodology_guide_110531.pdf)



Legend: GORTEC Groupe d'Oncologie Radiotherapie des tumeurs de la Tete Et du Cou, HNFIC Head and Neck French InterGroup, international Head and Neck Cancer experts.

CONFLICT OF INTEREST

Title page : **Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: a GORTEC internationally-reviewed consensus**

Florent Carsuzaa¹, Michel Lapeyre², Vincent Gregoire³, Philippe Maingon⁴, Arnaud Beddok⁵, Pierre-Yves Marcy⁶, Julia Salleron⁷, Alexandre Coutte⁸, Severine Racadot³, Yoann Pointreau⁹, Pierre Graff¹⁰, Beth Beadle¹¹, Karen Benezery¹², Julian Biau², Valentin Calugaru⁵, Joel Castelli¹³, Melvin Chua¹⁴, Alessia Di Rito¹⁵, Melanie Dore¹⁶, Pirus Ghadjar¹⁷, Florence Huguet¹⁸, Pauline Jardel¹⁹, Jorgen Johansen²⁰, Randall Kimple²¹, Marco Krengli²², Sarbani Laskar²³, Lachlan Mcdowell²⁴, Anthony Nichols²⁵, Silke tribius²⁶, Izaskun Valduvico²⁷, Chaosu Hu²⁸, Xavier Liem²⁹, Antoine Moya-Plana³⁰, Ida D'onofrio³¹, Upendra Parvathanen³², Vinita Takiar³³, Ester Orlandi³⁴, Amanda Psyrris³⁵, George Shenouda³⁶, David Sher³⁷, Conor Steuer³⁸, Xu Shan Sun³⁹, Yungan Tao³⁰, David Thomson⁴⁰, Mu-Hung Tsai⁴¹, Noemie Vulquin⁴², Philippe Gorphe³⁰, Hisham Mehanna⁴³, Sue S. Yom⁴⁴, Jean Bourhis⁴⁵, Juliette Thariat⁴⁶

Conflict of Interest: no conflicting relationship exists for any author.